Erratum to: Test-retest analysis of a non-invasive method of quantifying [11C]-PBR28 binding in Alzheimer’s disease (EJNMMI Research, (2016), 6, 1, (72), 10.1186/s13550-016-0226-3);Test-retest analysis of a non-invasive method of quantifying [11C]-PBR28 binding in Alzheimer’s disease

EJNMMI Research

Volumn 6, Issue 1, 2016, Pages

  Nair, Akshay ^a   Veronese, Mattia ^b   Xu, Xiaohui ^b,c   Curtis, Charles ^b,c   Turkheimer, Federico ^b   Howard, Robert ^a   Reeves, Suzanne ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c King s College London   (United Kingdom)

Author keywords

Alzheimer s; Dementia; Inflammation; Microglia; Positron emission tomography

Indexed keywords

PBR28 [11C]; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; FEMALE; GENOTYPE; HUMAN; MALE; MMSE SCORE; NERVE DEGENERATION; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEST RETEST RELIABILITY; VERY ELDERLY;

EID: 84988909497     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-017-0256-5     Document Type: Erratum

References (16)

1. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463–77. doi:10.1038/nri3705.
2. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118(1):1–17. doi:10.1016/j.pharmthera.2007.12.004.
3. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016. doi:10.1016/j.jalz.2016.02.010
4. Varley J, Brooks DJ, Edison P. Imaging neuroinflammation in Alzheimer’s disease and other dementias: recent advances and future directions. Alzheimers Dement. 2015;11(9):1110–20. doi:10.1016/j.jalz.2014.08.105.
5. Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48(1):158–67.
6. Kim S, Nho K, Risacher SL, Inlow M, Swaminathan S, Yoder KK, et al. Gene variation and microglial activity on [C]PBR28 PET in older adults at risk for Alzheimer’s disease. Multimodal Brain Image Anal (2013). 2013;8159:150–8. doi:10.1007/978-3-319-02126-3_15.
7. Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409–14. doi:10.1016/j.nicl.2015.01.009.
8. Lyoo CH, Ikawa M, Liow JS, Zoghbi SS, Morse CL, Pike VW, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. 2015;56(5):701–6. doi:10.2967/jnumed.114.146027.
9. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. doi:10.1016/j.jalz.2011.03.005.
10. Molloy DW, Standish TI. A guide to the standardized mini-mental state examination. Int Psychogeriatr. 1997;9 Suppl 1:87–94. discussion 143-50.
11. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1–5. doi:10.1038/jcbfm.2011.147.
12. Owen DR, Guo Q, Kalk NJ, Colasanti A, Kalogiannopoulou D, Dimber R, et al. Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab. 2014;34(6):989–94. doi:10.1038/jcbfm.2014.46.
13. Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015;42(7):1081–92. doi:10.1007/s00259-015-3043-4.
14. Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, et al. Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging. 2016;43(1):173–83. doi:10.1007/s00259-015-3149-8.
15. Anderson AN, Pavese N, Edison P, Tai YF, Hammers A, Gerhard A, et al. A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage. 2007;36(1):28–37. doi:10.1016/j.neuroimage.2007.02.017.
16. Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015;43(4):586–92. doi:10.1042/BST20150058.